Trial · NCT00000135
Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
NCT00000135, Phase 2, Phase 3, Completed, Johns Hopkins Bloomberg School of Public Health; results first posted 2015-11-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT). Trials, record NCT00000135. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000135
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
- NCT number
- NCT00000135
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 209 participants, actual
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Conditions
- HIV Infections, Cytomegalovirus Retinitis
- Interventions
- MSL-109, Placebo
- First posted
- 1999-09-24
- Last updated
- 2015-11-17
- Results first posted
- 2015-11-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality Rate | All patients enrolled were followed for a 17 month period or until a common study closing date | to evaluate the efficacy of an intravenous human monoclonal antibody to cytomegalovirus (CMV), MSL-109, as adjuvant treatment for CMV retinitis. . |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mortality Rate | All patients enrolled were followed for a 17 month period or until a common study closing date | deaths per person-year | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mortality Rate | MSL-109 | 0.68 | deaths per person-year | ||
| Mortality Rate | Placebo | 0.31 | deaths per person-year |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MSL-109 | 104 | |
| Overall Study | STARTED | Placebo | 105 | |
| Overall Study | COMPLETED | MSL-109 | 77 | |
| Overall Study | COMPLETED | Placebo | 91 | |
| Overall Study | NOT COMPLETED | MSL-109 | 27 | |
| Overall Study | NOT COMPLETED | Placebo | 14 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MSL-109 | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | MSL-109 | 0 | 104 |
| Total, other adverse events | Placebo | 0 | 105 |
| Total, serious adverse events | MSL-109 | 0 | 104 |
| Total, serious adverse events | Placebo | 0 | 105 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| MSL-109 vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000135
GET https://conductscience.org/api/trials/v1/NCT00000135/registered